Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab for refractory PED in neovascular age-related macular degeneration
ChiCTR2400082177Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Jul 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of faricimab in exudative macular degeneration, sponsored by Shanghai General Hospital. Primary endpoint: Change in height of pigment epithelium detachment from baseline at 6 months. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
faricimab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR2400082177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082177.